SALT LAKE CITY, July 24, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its second quarter 2024 operating results on Wednesday, August 7, 2024, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day.
Conference Call Details
The conference call can be accessed by dialing 800-267-6316 for U.S. participants, or 203-518-9783 for international participants, and referencing conference ID “HCATQ224.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its clients leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
Health Catalyst Investor Relations Contact:
Jack Knight
Vice President, Investor Relations
+1 (855) 309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.
Health Catalyst Media Contact:
Tarah Neujahr Bryan
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$7.70 |
Daily Change: | -0.34 -4.23 |
Daily Volume: | 376,672 |
Market Cap: | US$465.620M |
August 27, 2024 August 08, 2024 August 08, 2024 August 07, 2024 May 21, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB